{
  "id": 15569319,
  "title": "Accession Therapeutics appoints Nicklasson as chairman",
  "url": "https://urgent.news/2026/10/19/accession-therapeutics-appoints-nicklasson-as-chairman",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-19T06:11:20.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/accession-therapeutics-appoints-nicklasson-as-chairman-93CH-4956408"
  },
  "original_language": "en",
  "account": "OXFORD, UK - Accession Therapeutics Limited announced the appointment of two new Non-Executive members to its board. Martin Nicklasson, with nearly four decades of experience in the biopharmaceutical industry, becomes the Non-Executive Chairman. He was previously the Chairman of Zealand Pharma and Kymab, which was acquired by Sanofi for $1.45 billion in 2021. Nicklasson has held board positions at Basilea Pharmaceutica and Nykode Therapeutics, previously served as CEO of Biovitum and SOBI, and worked in executive roles at Astra and AstraZeneca.\n\nPierre d’Epenoux, bringing over three decades of expertise in operational management, strategic planning, and business development, is appointed as Non-Executive Director. His most recent role was as CEO of ImCheck Therapeutics, an immuno-oncology company acquired by Ipsen for up to $1.2 billion in December 2025. D’Epenoux has held senior corporate development positions at Sanofi, Baxter Healthcare, and Merck KGaA. He currently chairs Elkedonia, a biotech company focused on neurology and depression.\n\nNick Cross, co-founder of Accession Therapeutics alongside CEO Bent Jakobsen in 2021, relinquishes the position of Executive Chairman but remains a director on the board. Accession Therapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies.",
  "summary": null,
  "key_points": [
    "Martin Nicklasson appointed as Accession Therapeutics Non-Executive Chairman",
    "Pierre d’Epenoux named Non-Executive Director at the biopharmaceutical company",
    "Nick Cross steps down as Executive Chairman but stays on the board"
  ],
  "editors_take": "Bringing in veteran leadership with deep experience in high-value acquisitions signals the company's intent to mature its board as it advances its clinical-stage cancer immunotherapy pipeline.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}